GlaxoSmithKline (NYSE: GSK) reported Q2 EPS of GBP0.51, GBP0.04 better than the analyst estimate of GBP0.47. Revenue for the quarter came in at GBP8.41 billion versus the consensus estimate of GBP8.25 billion.

• Growth outlooks: • 2026 guidance reaffirmed with expected growth in: turnover 3% to 5%; Core OP 7% to 9%; Core EPS 7% to 9% • On track for 2031 sales outlook of more than £40 billion; Accelerating growth from 2031 onwards • Operating margin stable to improving through dolutegravir loss of exclusivity period of 2028-2030

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.